Table 2.
Differences in baseline characteristics between KTRs with SARS-CoV-2 spike S1–specific IgG >35.2 BAU/ml versus those with <35.2 BAU/ml
| Characteristics | KTR SARS-CoV-2 Spike S1–Specific IgG Level | |
| >35.2 BAU/ml (n=10) | <35.2 BAU/ml (n=18) | |
| General | ||
| Age (yr), median (IQR) | 74 (64–81) | 65 (60–76) |
| Male sex, % | 70 | 72 |
| BMI (kg/m2)b | 25 | 26 |
| Diabetes, % | 10 | 11 |
| Malignancy, % | 50 | 39 |
| Transplantation | ||
| Time after transplantation (yr), median (IQR) | 12 (12–19) | 6 (3–11)a |
| History of previous transplantation | 1 | 1 |
| Baseline eGFR (ml/min per 1.73 m2), mean±SD | 44±23 | 47±18 |
| History of rejection within a year before vaccination, n (%) | 0 (0) | 0 (0) |
| Primary renal disease, n (%) | ||
| Glomerular | 6 (60) | 6 (33) |
| Vascular | 0 (0) | 2 (11) |
| Interstitial | 2 (20) | 1 (6) |
| Polycystic kidney disease | 2 (20) | 4 (22) |
| Diabetes | 0 (0) | 2 (11) |
| Other | 0 (0) | 3 (17) |
| Immunosuppression, n (%) | ||
| Triple therapy | 5 (50) | 17 (94) |
| Dual therapy | 5 (50) | 1 (6)a |
| Basiliximab | 5 (20) | 11 (44) |
| Tacrolimus | 8 (80) | 17 (94) |
| Ciclosporin | 2 (20) | 1 (6) |
| Mycophenolate mofetil | 6 (60) | 16 (89) |
| Azathioprine | 0 (0) | 1 (6) |
| Prednisolone | 9 (90) | 18 (100) |
KTR, kidney transplant recipient; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IQR, interquartile range; BMI, body mass index.
a
Significant difference between groups (P<0.05) using Mann–Whitney test.
b
Values represent mean values.